Avapritinib
- Generic Name
- Avapritinib
- Brand Names
- Ayvakit, Ayvakyt
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27FN10
- CAS Number
- 1703793-34-3
- Unique Ingredient Identifier
- 513P80B4YJ
- Background
Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis. It is one of the first medications available for the treatment of multidrug resistant cancers. Avapritinib shares...
- Indication
Avapritinib is indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
...
- Associated Conditions
- Advanced Systemic Mastocytosis (AdvSM), Aggressive Systemic Mastocytosis, Indolent Systemic Mastocytosis, Mast Cell Leukemia (MCL), Metastatic Gastrointestinal Stromal Tumor (GIST), Systemic Mastocytosis With an Associated Hematological Neoplasm, Unresectable Gastrointestinal stromal tumor
- Associated Therapies
- -
Avapritinib With Decitabine in Patients With SM-AHN
- Conditions
- Interventions
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-12-12
- Target Recruit Count
- 34
- Registration Number
- NCT06327685
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Mayo Clinic - Arizona, Phoenix, Arizona, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
- Conditions
- Interventions
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Children's Hospital of Soochow University
- Target Recruit Count
- 50
- Registration Number
- NCT06316960
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳Kaifeng Children's Hospital, Kaifeng, Henan, China
🇨🇳Third Xiangya Hospital of Central South University, Changsha, Hunan, China
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
- Conditions
- Interventions
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Children's Hospital of Soochow University
- Target Recruit Count
- 500
- Registration Number
- NCT06221683
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳XiangYa Hospital Central South University, Changsha, Hunan, China
🇨🇳Children's Hospital of Soochow University, Suzhou, Jiangsu, China
Avapritinib in CBF-AML With KIT Mutations
- Conditions
- Interventions
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2023-05-09
- Target Recruit Count
- 50
- Registration Number
- NCT05821738
- Locations
- 🇨🇳
First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 61
- Registration Number
- NCT05381753
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Drug-drug Interaction Study of Avapritinib and Midazolam
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT04908176
- Locations
- 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
Study for Patients Previously Treated in Avapritinib Clinical Trials
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 2
- Registration Number
- NCT04825574
- Locations
- 🇫🇷
Gustave Roussy Cancer Campus Grand Paris Institut de Cancerologie Gustave-Roussy, Villejuif, Val-de-Marne, France
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
- Conditions
- Interventions
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 37
- Registration Number
- NCT04773782
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
🇩🇪Universitaetsmedizin Göttingen, Göttingen, Lower Saxony, Germany
🇩🇪Hopp Children's Cancer Center, Heidelberg, Germany
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
- Conditions
- Anatomic Stage IV Breast Cancer AJCC V8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC V8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC V8Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC V8Locally Advanced Malignant Solid NeoplasmLocally Advanced MelanomaLocally Advanced Primary Malignant Central Nervous System NeoplasmLocally Advanced SarcomaMetastatic Malignant Solid NeoplasmMetastatic Melanoma
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT04771520
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Expanded Access Program for Avapritinib
- Conditions
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Blueprint Medicines Corporation
- Registration Number
- NCT04714086
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.